Form 4: Arcus Biosciences Director Kathryn Falberg Reports Significant Equity Grant and Stock Option Acquisition

Arcus Biosciences, Inc. Director Kathryn Falberg reported the acquisition of 13,300 restricted stock units and 38,300 stock options on June 10, 2025, as part of her compensation.

Summary

• Kathryn E. Falberg, a Director of Arcus Biosciences, Inc. (RCUS), reported changes in her beneficial ownership of company securities.
• On June 10, 2025, Ms. Falberg acquired 13,300 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs are set to vest in full on the earlier of June 10, 2026, or the next annual meeting of stockholders, and will fully vest upon a change in control of the company.
• Additionally, on June 10, 2025, Ms. Falberg acquired 38,300 Stock Options (Rights to Buy) with an exercise price of $10.02.
• These stock options will also vest in full on the earlier of June 10, 2026, or the next annual meeting of stockholders, and will become fully vested and exercisable upon a change in control.
• The stock options have an expiration date of June 9, 2035.
• Following these transactions, Ms. Falberg directly beneficially owns 68,600 shares of Common Stock and 38,300 Stock Options.
• She also indirectly beneficially owns 102,106 shares of Common Stock through a Trust.

Sentiment

Score: 7

Explanation: The filing reports a standard equity grant to a director, aligning their interests with the company's performance. This is a routine compensation event and generally viewed as a positive for corporate governance and incentivization, without indicating any negative operational or financial news.

Positives

• The grant of restricted stock units and stock options to a director aligns their financial interests with the long-term performance and shareholder value of Arcus Biosciences.
• The vesting schedule, including acceleration upon a change in control, provides incentives for the director to contribute to strategic outcomes.

Risks

• The value of the granted restricted stock units and stock options is subject to the future performance of Arcus Biosciences' stock price.
• The vesting of these equity awards is contingent on specific future dates or events (June 10, 2026, next annual meeting, or change in control), introducing a time-based risk for the recipient.

Future Outlook

The future outlook for the reported equity awards involves their vesting on the earlier of June 10, 2026, or the next annual meeting of stockholders, with accelerated vesting in the event of a change in control for Arcus Biosciences. The stock options are exercisable until June 9, 2035.

Industry Context

This Form 4 filing is a standard disclosure of insider equity compensation, a common practice across all industries, particularly in the biotechnology sector where equity incentives are a key component of executive and director compensation to align interests with long-term company growth and innovation.

Comparison to Industry Standards

• The grant of restricted stock units and stock options as part of director compensation is a widely accepted practice in the biotechnology industry and public companies globally, aiming to align the interests of directors with those of shareholders.
• While specific comparable companies or projects are not detailed in this filing, such equity grants are standard components of compensation packages for directors at companies like Gilead Sciences, Amgen, or Regeneron Pharmaceuticals, which also operate in the biopharmaceutical space and utilize similar incentive structures to attract and retain talent.

Management Changes

Corporate Governance

Related Party Transactions

• The acquisition of restricted stock units and stock options by Kathryn E. Falberg, a director, represents a compensation transaction between the company and a related party. This is a standard form of director compensation.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholder value, as the director's compensation is tied to the company's stock performance.
• Management: The Power of Attorney streamlines compliance processes for insider reporting, reducing administrative burden on the director and ensuring timely filings.

Next Steps

• Vesting of 13,300 Restricted Stock Units on the earlier of June 10, 2026, or the next annual meeting of stockholders.
• Vesting of 38,300 Stock Options on the earlier of June 10, 2026, or the next annual meeting of stockholders.
• Potential accelerated vesting of both RSUs and Stock Options upon a change in control of Arcus Biosciences.

Key Dates

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership, SEC Filing